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Introduction
Prognostic factors in breast cancer were stratified into
3 categories by a multidisciplinary group of experts of
the College of American Pathologists (CAP) in 1999
[1,2]. Category I included factors proven to be of prog-
nostic value in numerous studies, as tumor size, axil-
lary lymph node metastases, histological grade (G),
histological type, and estrogen and progesterone
receptor status. Category II comprised factors that had
been studied, but whose importance remains to be val-
idated: mitotic index, HER-2 overexpression, p53
mutation, expression of Ki-67, and peritumoral lym-
phatic or vascular channel invasion. Finally, category
III were other factors, not sufficiently studied and
demonstrated to be of prognostic factors only by some
investigators: DNA ploidy, tumor angiogenesis,
expression of EGFR, TGF-alpha, Bcl-2, pS2, and
cathepsin D. The fact that steroid receptors were
included in category I emphasizes their role in predict-
ing the prognosis and choice of a particular algorythm
of management in breast cancer patients. 
Recently, there is a tendency in English literature
on the subject to distinguish between prognostic fac-
tors, which are useful for determining the expected
further course of the disease, and predictive factors,
which determine the response to treatment (steroid
receptors and HER-2 overexpression) [1,2].
Normal function of the mammary glandular tissue
is regulated by various hormones, like steroid hor-
mones (i.e., estrogens, progestagens and androgens),
peptide hormones (insulin, growth hormone, pro-
lactin), and amino acid hormones (thyroid hormones).
Estrogens and progestagens regulate the epithelial
growth and morphogenesis of the ducts and alveoli of
the mammary gland. Changing activity of these hor-
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mones leads to the physiological changes in the breast
gland's density [3]. 
Apart from normal proliferation, morphogenesis
and physiological activity of mammary gland cells, the
steroid hormones also influence the development and
progression of breast cancer. The hormones' action on
the tissues starts after binding to specific receptor pro-
teins: steroid receptors. The steroid hormone recep-
tors: estrogen (ER), progesterone (PR), and androgen
(AR) belong to the superfamily of nuclear receptors
[4].
Nowadays, great hope is linked with finding out the
role that androgen receptors play in breast cancer, as
they belong to the same family of steroid hormone
receptors, and thus show high structural, functional,
and topographic similarity to the aforementioned
estrogen and progesterone receptors.
The purpose of our study was to evaluate the prog-
nostic role of androgen receptor status of breast cancer
cells in patients who underwent primary radical surgi-
cal treatment. Special consideration was given to the
following aspects:
1) determination of incidence of androgen receptor
expression on breast cancer cells in the analyzed
group of patients
2) evaluation of the response to different methods of
treatment depending on the androgen receptor sta-
tus of breast cancer cells
3) uni- and multivariate analysis of the prognostic and
predictive value of androgen receptor expression
on breast cancer cells considering different meth-
ods of adjuvant treatment (hormone therapy,
chemotherapy, and radiotherapy), based on the
course of the disease within 5 years after surgery.
Materials and methods
Patients. 488 adult females were included in the study, who
underwent primary radical surgery for breast cancer at the 2nd
Department of General and Oncological Surgery, Wroclaw Medi-
cal University, from 1996 to 2002. 428 patients (87.7%) had
Patey's conservative radical mastectomy and 60 (12.3%) Halsted's
radical mastectomy. The mean age at operation was 54.3, ranging
from 32 to 79. The mean length of hospitalization was 7.2 days for
the patients after Patey's mastectomy and  9.8 days for those after
Halsted's mastectomy. 
Hormone therapy was based on tamoxifen administered 20 mg
daily p.o. for 5 years. Adjuvant chemotherapy and radiotherapy
were given in accordance with the current standards recommended
by the Polish Union of Oncology. 
Postoperative hormone therapy was used in the largest number
of patients, either as a single measure (in 216 patients, 44.3%) or
combined with other methods: radiotherapy (40 patients, 8.2%),
chemotherapy (24, 4.9%), or both chemotherapy and radiotherapy
(48, 9.8%). Postoperative chemotherapy and radiotherapy was also
a frequent combination (72 patients, 14.8%) (Table 1).
On the other hand, patients after radical mastectomy infre-
quently underwent chemotherapy (16 patients - 3.3%) or radio-
therapy (4 patients - 0.8%) as a sole adjuvant treatment. In 68
patients (13.9%) surgery was the only therapeutic option used.
488 adult females underwent primary radical operations for
breast cancer at the 2nd Department of General and Oncological
Surgery in Wroclaw from 1993 to 2002. 
Immunohistochemistry. The expression of the androgen receptor
on cancer cells was detected immunohistochemicaly. 4 μm paraf-
fin sections were used, mounted on silanized slides (DAKO, cat.
No. S 3003). The specimens were then deparaffined with xylene
and passed through a graded ethanol series of decreasing concen-
trations, down to pure water. The antigen of tissues fixed with for-
malin was retrieved with Target Retrieval Solution (DAKO, cat.
No. S 1700) by warming in water bath at 96°C for 20 min. Endoge-
nous peroxydase was blocked by 3% H2O2 for 10 min. Afterwards
the slides were treated with primary antibodies: Monoclonal
Mouse Anti Human Androgen Receptor Clone, AR441 (DAKO,
cat. No. M3562), diluted 1/50, incubated for 30 min. at ambient
temperature. Thus prepared slides were rinsed with TBS and then
biotinylated antibody (LSAB+ kit, DAKO) was added for 15 min.
After rinse with TBS, the slides were incubated with streptavidin-
peroxidase complex (LSAB+ kit, DAKO, cat. No. K 0675) for 15
min. The immunocytochemical reaction was triggered by 3,3-
diaminobenzidine tetrahydrochloride (DAB+ Liquid,  DAKO, cat.
No. K 3486). The slides were then rinsed in running water and
dehydrated in graded ethanol series. Finally, the slides were treat-
ed with xylene and embedded in balsam.
To assess the value of the androgen receptor on cancer calls as
an independent prognostic factor, a correlation was sought between
its expression and selected well-documented prognostic factors (5-
year survival rate after surgery, incidence of local recurrences, and
symptom-free survival time). 
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Fig. 1. Distribution of expressed different
steroid receptors on breast cancer cells in
female patients who underwent radical mas-
tectomy in the years 1993-2002.
The course of disease within 5 years of the operation was also
included in the analysis, considering the survival time, local recur-
rences, symptom-free survival time, in relation to the adjuvant
treatment used and the expression of the androgen receptor. This
allowed determination of predictive value of the androgen receptor
expression on cancer cells.
The information was obtained either personally during routine
follow-up visits, or by phone or mail from the patients and their
families. 
Ethical issues. The permission to carry out this work was given by
Polish Bioethical committee, Wroclaw Medical University, Nr. KB
- 478/2006.
Statistical analysis. All the aforementioned data were organized
with MS Excel. The relationship between different patient-related
factors or the course of disease after surgery and the expression of
androgen receptors on cancer cells was tested by Pearson's Chi-
square test. Significance was set at the level of p<0.05. 
Results
From 1993 to 2002, primary radical operations for
breast cancer were performed in 488 female patients.
They underwent either Halsted's mastectomy or
Patey's mastectomy and these operations accounted for
3.7% of all surgical procedures made in that time at the
2nd Department of General and Oncological Surgery,
Wroclaw Medical University.
The androgen receptor was determined to be
expressed on cancer cells of the excised mammary
glands in 212 patients, i.a., 43.4% of all the patients
operated on for breast cancer (Group 1, androgen
receptor positive, AR (+) (Fig. 1). In 276 patients
(56,6%) the androgen receptor was not found to be
expressed on cancer cells (Group 2, androgen receptor
negative, AR (-).
The estrogen receptor was slightly less common,
found in 192 patients (39.3%). The progesterone
receptor was detected least frequently, in 120 patients
(24.6%) (Table 2). 
The prognostic value of androgen receptor expres-
sion was evaluated on the basis of the analysis of 5-
year survival rate after surgery, incidence of local
recurrences, and symptom-free survival time. 
The mean rate of 5-year survival for the total num-
ber of mastectomized female patients was 59.8%. For
the group of breast cancer patients with expressed
androgen receptor this 5-year survival rate was higher,
71.7%, whereas for the androgen receptor-negative
patients it was lower, 50.7%. However, the difference
was not statistically significant (p=0.19).
The analysis also comprised the incidence of local
recurrences and symptom-free survival time in the two
different groups within 5 years of the operation. Local
recurrences were found much more frequently in the
androgen receptor-negative patients (144 patients,
52.2% of Group 2). In Group 1 local recurrences were
present in 48 androgen receptor-positive patients,
22.6%. Among the patients who actually had recur-
rence of breast cancer, the rate of women with
expressed androgen receptor was lower than in the
whole study group of patients after radical surgery for
breast cancer (25%). The difference was statistically
significant (p=0.023) (Table 3). 
420 of 488 mastectomized patients qualified for
adjuvant therapy (86.1%). 160 patients (32.8%) under-
went adjuvant chemotherapy, 164 (33.6%) postopera-
tive radiotherapy, and 328 (67.2%) hormone therapy
(Table 4). 
Also the symptom-free survival time was statisti-
cally significantly shorter for Group 2 (3.02 years)
compared to Group 1, androgen receptor-positive
(4.08 years) (p=0.0001).
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Table 1. Distribution of different methods of adjuvant treatment
used in female patients with breast cancer who underwent radical
mastectomy in the years 1993-2002.
Table 2. Incidence of various combinations of coexisting steroid
receptors in female patients with breast cancer who underwent rad-
ical mastectomy in the years 1993-2002.
Table 3. Incidence of local recurrences within 5 years of surgery
among female patients who underwent radical mastectomy in the
years 1993-2002.
Most of the patients who underwent mastectomy
(420, 86.1%) had also adjuvant therapy: chemothera-
py, radiotherapy, and/or hormone therapy. 
Different modes of adjuvant therapy were used in a
similar number of patients from both groups. 
The relation between androgen receptor expres-
sion on breast cancer cells and the patients' positive
response to adjuvant treatment was evaluated by the
analysis of 5-year survival rate after surgery, inci-
dence of local recurrences, and symptom-free sur-
vival time.
The influence of androgen receptor expression on
the beneficial therapeutic effect of hormone therapy
was found to be statistically significant. For the andro-
gen receptor-positive patients who were given adju-
vant hormone therapy the 5-year survival rate was
higher, symptom-free survival time longer, and the
incidence of local recurrences lower as compared with
both the androgen receptor-positive patients who did
not receive hormone therapy, and with those androgen
receptor-negative patients who were given hormone
therapy postoperatively. All the above differences
were statistically significant (p<0.05) (Table 5). On the
other hand, the 5-year survival rate was lower, symp-
tom-free survival time shorter, and the incidence of
local recurrences higher among those women who
were administered adjuvant hormone therapy and/or
radiotherapy after radical surgery compared with the
patients who had none of the above adjuvant therapy,
both AR (+) and AR (-) (p<0.05). The androgen recep-
tor-positive patients developed better response to
chemotherapy and radiotherapy than the androgen
receptor-negative patients, though the differences were
not significant statistically (p>0.05) (Tables 6 and 7).
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Table 4. Methods of adjuvant treatment used in female patients
with who underwent radical mastectomy in the years 1993-2002. 
Table 7. Therapeutic efficacy of radiotherapy in female patients who underwent radical mastectomy in the years 1993-2002.
Table 6. Therapeutic efficacy of chemotherapy in female patients who underwent radical mastectomy in the years 1993-2002.
Table 5. Therapeutic efficacy of hormone therapy in female patients who underwent radical mastectomy in the years 1993-2002.
Tables 5-7: AR (+) - androgen receptor positive, AR (-) - androgen receptor negative 
Discussion
The results of treatment of breast cancer are not satis-
factory yet. Every year 4000 women die in Poland for
this malignancy, which gives 40% mortality. Many
randomized clinical trials, retrospective analyses and
metaanalyses indicate that the greatest chance for cure
is associated with adequate adjuvant treatment:
chemotherapy, hormone therapy, and radiotherapy.  
Prognostic factors, factors responsible for positive
reaction to treatment, and various grading systems of
this malignant disease facilitate making therapeutic
decisions optimal for the patient. The value of some of
these factors has already been well proven (e.g. G fea-
ture, status of axillary lymph node metastasis, estrogen
and progesterone receptor, BRCA gene mutation), and
the usefulness of others is being verified (HER2 over-
expressionmutations of genes involved in regulation of
the cell cycle, angioinvasion and neuroinvasion, or
micrometastasis). 
Understanding the role of estrogen and proges-
terone receptor in pathogenesis of breast cancer made
it possible to use this knowledge in practice in the 50's
of the past century for determining adjuvant treatment
of women with this disease. 
Recently, prognostic value in breast cancer has also
been attributed to the androgen receptor (AR). Studies
on induced breast cancer cells in rats have demonstrat-
ed that AR is the steroid receptor most commonly
expressed on the cells of primary and metastatic breast
tumors [5]. According to different investigators, the
incidence of AR expression in breast cancer patients is
from 35% [6] to 90% [5]. 
Such common expression of AR on breast cancer
cells brings about the question of the role of androgens
in the pathogenesis of human breast cancer. The role of
AR in breast cancer was already noticed 30 years ago.
Persijn, in a short communication, observed that
expression of AR in 51 patients was a determinant of
better response to treatment with ethinyl estradiol [7].
Experiments on animals prove that androgens may
induce tumor growth. Also proliferation of the tumor
in human mammary gland seems to be modified by
androgens. Androgens may have stimulating or
inhibitory effect on tumor growth. These apparently
paradoxal contradictory effects of steroid hormones
are probably due to the mediation of ER and/or PR.
Androgens show two main effects on cancer cells of
the mammary gland. When estrogens are lacking, they
stimulate tumor growth by direct binding to ER alpha;
this effect is blocked by antiestrogens. When estrogens
are present, however, androgens act as their antago-
nists and inhibit the growth of the tumor; this is prob-
ably mediated by AR and can be blocked by antian-
drogens [8]. The clinical consequence of such influ-
ence of androgens on cell receptors is poor prognosis
of those female patients receiving hormone therapy,
whose cancer cells do not show AR expression. Many
authors emphasize that expression of AR in breast
tumors is a favorable prognostic factor, while the lack
of AR correlates with a higher grade of malignancy
[9-12]. 
AR (-) patients show worse response to hormone
therapy that AR (+) women. Teulings has observed that
regression of tumor in 34 patients who received mege-
strol acetate was associated with high concentrations
of AR [13]. Therefore testing AR may be important for
the choice of therapy, especially for patients with high
proliferative activity of the tumor. In 1984 Bryan
observed in a group of 1371 breast cancer patients that
AR (+) had better response to treatment and higher 
5-year survival than AR (-) ones [14]. On the other
hand, Allegra stated that AR expression in patients
with advanced tumors was not associated with better
response to hormone therapy [15]. Thus the expression
of AR and ER on cancer cells may have additional
therapeutic consequences, particularly for tumors
showing high proliferative activity and AR expression
as the sole steroid receptor. The absence of AR corre-
lates with higher malignancy and poorer response to
hormone therapy in AR (-) women.
Research made in numerous centers all over the
world have clearly proven that estrogen and proges-
terone receptors cannot be considered as independent
prognostic factors of survival, but that their expression
determines positive response to hormone therapy, thus
enhancing the probability of complete cure of the
operated woman. Having this in mind, demonstrating
an association between androgen receptor and the
expression of the other types of steroid receptors could
make indications for hormone therapy stronger or
weaker, especially in correlation with the analysis of
response to adjuvant treatment within particular
groups of patients.  
It has been demonstrated that the expression of
androgen receptor on cancer cells is often accompa-
nied by the expression of estrogen receptor, and even
more frequently progesterone receptor [16-19]. There-
fore many authors maintain that knowing the status of
all the three types of steroid receptors will facilitate
predicting more accurately the response of patients to
hormone therapy [16-21].
The role of androgens and their receptor in the pro-
gression of breast cancer remains unexplained [22-25].
Many studies showed that elevated level of androgens
is directly proportional to the risk of developing breast
cancer in postmenopausal women [26-30]. Clinical tri-
als have demonstrated that taking antiandrogens and
blocking the androgen receptor correlates with the
increased incidence of breast cancer [31-33]. In our
study, lower 5-year survival rate was demonstrated in
women with breast cancer without androgen receptor
expression (50.7% patients of Group 2). The prognosis
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for patients with positive androgen receptor expression
was better: 5-year survival rate of 71.7%. The above
difference in survival was not statistically significant,
however. Therefore androgen receptor expression can-
not be considered as an independent prognostic factor
for breast cancer. 
The analysis of incidence of local recurrences and
symptom-free survival time in separate study groups
has shown that the number of local recurrences was
lower in Group 1 (22.6% in Group 1 vs. 52.2% in
Group 2), and symptom-free survival time in this
group was longer (4.08 years in Group 1 vs. 3.06 in
Group 2). 
Our results are consistent with those presented by
Shippinger, who found the mean survival time after
recurrence to be significantly longer in AR (+) patients
(21.89 months vs. 11.99 months) [34]. Correno did not
observe any statistically significant association
between AR expression and local recurrences [35],
which, however, has not been confirmed in our study.
In most our patients who underwent surgery adju-
vant treatment was given: chemotherapy, radiotherapy,
and/or hormone therapy. The distribution of corre-
sponding methods of adjuvant treatment among
steroid receptor-positive and negative patients was
similar in both groups. It was Thus the method of adju-
vant treatment did not affect the differences in long-
term results in the two groups, AR (+) and AR (-). The
5-year survival rate was proven to be higher, local
recurrence rate lower, and symptom-free survival time
longer for the androgen receptor-positive patients who
received adjuvant hormone therapy compared with the
androgen receptor-negative patients with the same
adjuvant therapy. The androgen receptor-positive
patients who received adjuvant hormone therapy had
also more favorable prognosis than those androgen
receptor-positive patients in whom hormone therapy
was not used. Our results are in agreement with those
presented by Bryan, who demonstrated that the
response to treatment of androgen receptor-negative
patients is worse than that of androgen receptor-posi-
tive patients. AR (-) patients had shorter survival time
than the AR (+) patients [36].
The relatively more aggressive course of the malig-
nant disease and in consequence worse prognosis
noted in patients who received radiotherapy or
chemotherapy in comparison to those who did not
receive these methods of adjuvant treatment was not
related to the expression of androgen receptor. These
results were most probably the consequence of the
fact, that according to the recommendations of Polish
Union of Oncology patients with more advanced can-
cer were qualified for adjuvant chemotherapy and
radiotherapy. 
Also the inhibitory effect of androgens on breast
cancer cell cultures with expressed androgen receptor
has been proven [37]. Zhou investigated the influence
of estrogens, either alone or in combination with prog-
esterone and testosterone, administered for 3 days.
Estrogens alone caused a 6-fold increase of prolifera-
tion of mammary gland epithelium and increase of
estrogen receptor expression by about 50%. Estrogens
combined with testosterone led to a decrease of epithe-
lial proliferation by 40% and the expression of estro-
gen receptor [38]. These observations prove that
androgens can inhibit the estrogen-induced prolifera-
tion of mammary gland epithelium, and their addition
to substitution hormone therapy may reduce the risk of
breast cancer. Xie in experimental studies on Noble rat
model proved that combined administration of estro-
gens and testosterone to female rats induces the devel-
opment of breast cancer. The dose of testosterone only
influenced the time of the onset of the disease, but
seemed to be irrelevant to the development of cancer
itself, both in female and male rats [39-42]. This team
of investigators demonstrated also that testosterone
alone or in combination with 17-beta-oestradiol leads
to overexpression of androgen receptor on follicular
and ductal epithelium cells of the mammary gland
[39].
Hardin demonstrated anti-cancer efficacy of dehy-
droepiandrosterone sulfate (DHEAS) in the treatment
of tumors that lacked estrogen and progesterone recep-
tors and had androgen receptor expressed. In his opin-
ion DHEAS may be an effective therapeutic option for
the patients with positive androgen receptors not
receiving standard hormone therapy. This was support-
ed by experiments in vitro, in which introduction of
the gene for androgen receptor to cells primarily
deprived of all the three types of steroid receptors led
to their destruction by DHEAS and aromatase
inhibitors [43].
The clinical role of androgen receptor (AR) in
breast cancer is much less documented than that of
estrogen and progesterone receptors.
Though the expression of androgen receptor in
male breast cancer has been investigated by some
authors, the articles on this subject considering female
breast cancer are very scarce. There are several theo-
retical arguments supporting such considerations.
First, androgen receptor belongs to the same nuclear
receptor superfamily as estrogen and progesterone
receptor. Therefore their mechanisms of action are
similar. Nowadays it is also known that apart from the
effector mechanism of their stimulation, which con-
sists in direct binding with DNA and regulating the
processes of transcription and translation, their action
can also be mediated by a cascade of second transmit-
ters like membrane receptors. This opens a possibility
of mutual modulation of the transmission path in the
cell, thanks to the activation of different signal trans-
mission paths inside the cell. Moreover, steroid hor-
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mones, agonists of estrogen, progesterone, and andro-
gen receptors, due to their similar chemical structure
can react not only with the specific receptor but also
cross-react with the other two types of steroid recep-
tors. Obviously, in the latter instance the reaction will
be much weaker than with the main receptor, but when
the concentration of the receptors is high this other
way of signal transmission may play an important role
in pathogenesis, too. One should also have in mind that
in normal physiology steroid hormones can be con-
verted into each other, i.a., androgens may undergo
peripheral conversion to estrogens in the fatty tissue.
Possible associations between the expression of
androgen receptor in cancer cells and other prognostic
factors and those determining the response to treat-
ment need further analysis, which might elucidate the
indications for choosing one of the available therapeu-
tic options or facilitate prognosing the further course
of disease. This might be particularly beneficial to the
patients who are androgen receptor-positive and both
estrogen and progesterone-negative. In about 10% of
all female patients the androgen receptor is the only
steroid receptor detected on breast cancer cells.
According to the present recommendations, these
patients are not qualified for hormone therapy. There-
fore clearing the prognostic and therapeutic role of
androgen receptor in women with breast cancer may
turn out to be another milestone in our fight with this
disease.
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